Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 37, 2020 - Issue 6
Submit an article Journal homepage
385
Views
11
CrossRef citations to date
0
Altmetric
Articles

A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies

John GoldbergPediatric Oncology, Dana-Farber/Children’s Hospital Cancer Center; Correspondence[email protected]
View further author information
,
Maria Luisa SulisMemorial Sloan Kettering Cancer Center; View further author information
,
Julia BenderMemorial Sloan Kettering Cancer Center; View further author information
,
Sima JehaSt. Jude Children’s Research Hospital, Pediatrics; View further author information
,
Rebecca GardnerSeattle Childrens Hospital, Pediatric Hematology Oncology; View further author information
,
Jessica PollardBlood Disorders Center/Children’s Hospital Cancer Center; View further author information
,
Victor AquinoDepartment of Pediatrics, University of Texas Southwestern Medical Center at Dallas; View further author information
,
Theodore LaetschDepartment of Pediatrics, University of Texas Southwestern Medical Center at Dallas; View further author information
,
Naomi WinickDepartment of Pediatrics, University of Texas Southwestern Medical Center at Dallas; View further author information
,
Cecilia FuDivision of Pediatric Hematology/Oncology, CHLA; View further author information
,
Leigh MarcusFood and Drug Administration; View further author information
,
Weili SunCity of Hope National Medical Center; View further author information
,
Anupam VermaUniversity of Utah School of Medicine, Pediatric hematology Oncology; View further author information
,
Michael BurkeChildren’s Hospital of Wisconsin; Medical College of Wisconsin; View further author information
,
Phoenix HoMedpace, Cincinnati, OH; View further author information
,
Thomas ManleyMedpace, Cincinnati, OH; View further author information
,
Rajen ModyUniversity of Michigan. Oesterheld, Javier; ;Levine Children’s Hospital, Pediatric Hematology-Oncology; View further author information
,
Wendy TchengChildren’s Hospital Central California; View further author information
,
Blythe ThomsonMedpace, Cincinnati, OH; View further author information
,
Julie ParkSeattle Childrens Hospital, Pediatric Hematology Oncology; View further author information
,
Richard SpostoUniversity of Southern California; View further author information
,
Yoav MessingerChildren’s Hospitals and Clinics of Minnesota, Cancer and Blood Disorders; ORCID Iconhttp://orcid.org/0000-0001-7990-1802View further author information
ORCID Icon,
Nobuko HijiyaColumbia University; View further author information
,
Paul GaynonDivision of Pediatric Hematology/Oncology, CHLA; View further author information
&
Julio BarredoDivision of Pediatric Hematology-Oncology, University of Miami Miller School of MedicineView further author information
 show all
Pages 465-474 | Received 03 Feb 2020, Accepted 02 Apr 2020, Published online: 27 Apr 2020

References

  • Bhatia S, Robison L. In: Fisher DE, Look Orkin, AT, Lux SE, Ginsburg D, Nathan DG, eds. Oncology of Infancy and Chilhood. Vol. 1. CH. 1, Philadelphia (PA): Saunders Elsevier, 2009.
  • Reiter AF, AA. In: Fisher DE, Look Orkin AT, Lux SE, Ginsburg D, Nathan DG, eds. Oncology of Infancy and Childhood. Vol. 1. Ch. 13, Philadelpha (PA): Saunders Elsevier, 2009.
  • Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579–587. (2005). doi:10.1111/j.1365-2141.2005.05773.x.
  • Scuto A, Kirschbaum M, Kowolik C, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008;111(10):5093–5100. doi:10.1182/blood-2007-10-117762.
  • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. doi:10.1182/blood-2006-06-025999.
  • Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623–3629. doi:10.1200/JCO.2009.25.9119.
  • Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014;89(9):889–895. doi:10.1002/ajh.23778.
  • Burke MJ, Bhatla T. Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr. 2014;2:42. doi:10.3389/fped.2014.00042.
  • Stubbs MC, Kim W, Bariteau M, et al. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 2015;21(10):2348–2358. doi:10.1158/1078-0432.CCR-14-1290.
  • Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Invest Drugs . 2013;22(9):1211–1223. doi:10.1517/13543784.2013.815165.
  • Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197–2203. doi:10.1200/JCO.2011.38.1350.
  • Burbury KL, Bishton MJ, Johnstone RW, et al. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol. 2011;90(7):847–849. doi:10.1007/s00277-010-1099-6.
  • Wood PJ, Strong R, McArthur GA, et al. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. Cancer Chemother Pharmacol. 2018;82(3):493–503. doi:10.1007/s00280-018-3634-4.
  • Novartis. NDA 205353 FARYDAK (panobinostat) RISK EVALUATION AND MITIGATION STRATEGY (REMS) 2015.
  • Tzogani K, Hennik PV, Walsh I, et al. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. The Oncol. 2018;23(7):870–870. doi:10.1634/theoncologist.2017-0301.
  • DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–1636. doi:10.1038/leu.2013.38.
  • Van Veggel M, Westerman E, Hamberg P. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. Clin Pharmacokinet. 2018;57(1):21–29. doi:10.1007/s40262-017-0565-x.
  • Imai Y, Maru Y, Tanaka J. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci. 2016;107(11):1543–1549. doi:10.1111/cas.13062.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.